The 98-Patient Case Series That Shaped Cannabinoid Hyperemesis | Research

The takeaway

In a single-center review, most under-50 patients with recurrent vomiting and cannabis exposure were frequent, long-term users, and hot showers commonly eased symptoms.

Read this if you want a data-backed snapshot of how clinicians first characterized cannabinoid hyperemesis and which clinical clues they relied on.

91%
of patients with documented bathing behavior reported symptom relief with hot showers or baths

What the researchers found

Across 98 patients under age 50 with recurrent vomiting and prior cannabis exposure, the pattern was consistent. Among those with duration data, over two-thirds reported using cannabis for more than two years before symptoms began. Among those with frequency data, nearly all used more than once per week. Abdominal pain was reported by 86 percent of the cohort.

Hot water exposure stood out. Of 57 patients with bathing behavior recorded, 91 percent said hot showers or baths relieved symptoms. That odd but recurring detail helped crystallize a clinical picture that had been emerging in scattered case reports.

Follow-up was sparse. Only 10 patients had outcome data after the initial visit. Of those 10, seven reported stopping cannabis and six of those seven reported complete resolution of symptoms. With such a small and selective subset, that association should be interpreted cautiously.

Based on these descriptive data, the authors proposed major and supportive diagnostic criteria for cannabinoid hyperemesis, aiming to standardize how it is identified.

Why it matters

By 2012, clinicians were seeing patients with cyclic vomiting, abdominal pain, and a peculiar report that hot showers gave relief. Individual case reports were accumulating, but a larger, structured series had been missing. This study gathered nearly 100 such patients into one dataset, described the shared features, and outlined criteria that many clinicians began using to recognize cannabinoid hyperemesis in practice.

The numbers in context

- Cohort yield: 98 of 1,571 screened records (6 percent) met case definition

- Age: all patients were younger than 50 years

- Long-term exposure: 25 of 37 with duration data used cannabis more than 2 years before symptom onset (68 percent)

- Frequent use: 71 of 75 with frequency data used more than once weekly (95 percent)

How the study worked

Retrospective case series from a single academic center. Electronic medical records from January 1, 2005 to June 15, 2010 were screened. Inclusion required recurrent vomiting without another identified cause and cannabis use preceding symptom onset. Of 1,571 records initially identified, 98 patients met inclusion criteria. Symptom features, cannabis exposure history, and bathing behavior were abstracted when documented. Follow-up information was available for only 10 patients. No control group and no standardized toxicology confirmation were reported in the abstract.

Who was studied

N=98 patients younger than 50 years, diagnosed with cannabinoid hyperemesis, Country not specified.

What this study cannot tell us

Single-center retrospective design with no control group. Case identification relied on chart documentation and clinician judgment, which introduces selection and misclassification risk. Key exposure variables were missing for many patients, including exact duration, dose, product type, and potency. Hot bathing behavior was only documented for a subset. Only 10 percent had follow-up data, and cessation was self-reported without objective verification. The series included only patients under 50, limiting generalizability to older adults.

How to read the evidence

Rated preliminary: a retrospective case series without controls, substantial missing data, and only 10 percent follow-up. Useful for hypothesis generation and descriptive criteria but not for establishing causation or frequency.

When this study was published

Published in 2012 using records from 2005-2010. Product types and potencies have shifted since then, and patterns of use in current markets may differ from those captured here.

The bigger picture

Cannabinoid hyperemesis has been easy to miss because its core symptoms overlap with other conditions like cyclic vomiting syndrome and gastroparesis. This series helped codify a recognizable profile: younger age, frequent long-term cannabis exposure, recurrent vomiting with abdominal pain, and relief with hot bathing. The resolution reported by most of the few who stopped using cannabis suggests a potential exposure-outcome link, but the limited and selective follow-up means that conclusion cannot be generalized from this dataset alone. The proposed diagnostic criteria from this paper influenced how CH is discussed and documented, even as unanswered questions remain about mechanisms, risk factors, and prevalence.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

What biological mechanism links symptom relief to hot showers or baths?
Which exposure patterns or product types, including potency and cannabinoid profiles, are most associated with this syndrome?
How common is cannabinoid hyperemesis in the broader population of frequent users, and are there identifiable genetic or metabolic risk factors?
How well do the proposed diagnostic criteria perform when tested prospectively against similar conditions like cyclic vomiting syndrome?

Common questions

What is cannabinoid hyperemesis?

A clinical syndrome characterized by recurrent nausea and vomiting in the context of cannabis exposure, often accompanied by abdominal pain and reports that hot showers or baths temporarily relieve symptoms.

How common was hot shower relief in this series?

Among 57 patients with bathing behavior recorded, 52 reported relief with hot showers or baths, which is 91 percent of that subgroup.

Did symptoms go away when people stopped using cannabis?

Among the 10 patients with follow-up, seven reported stopping cannabis and six of those seven reported complete resolution. That is a small, selective subset and cannot establish what would happen in the broader group.

Read the original research

Cannabinoid hyperemesis: A case series of 98 patients

Mayo Clinic Proceedings, 87(2), 114-119

Mayo Clinic Proceedings is a peer-reviewed medical journal with a high level of credibility and prestige.

View on PubMed ↗Publisher’s paper ↗

Citation

Simonetto, Douglas A.; Oxentenko, Amy S.; Herman, Mark L.; Szostek, Jason H.. (2012). Cannabinoid hyperemesis: A case series of 98 patients. Mayo Clinic Proceedings, 87(2), 114-119. https://doi.org/10.1016/j.mayocp.2011.10.005